HC Wainwright Forecasts Mural Oncology Q3 Earnings

Mural Oncology plc (NASDAQ:MURA) – Investment analysts at HC Wainwright issued their Q3 2024 earnings per share (EPS) estimates for shares of Mural Oncology in a report released on Thursday, October 17th. HC Wainwright analyst A. Maldonado forecasts that the company will earn ($2.06) per share for the quarter. HC Wainwright has a “Buy” rating and a $18.00 price objective on the stock. The consensus estimate for Mural Oncology’s current full-year earnings is ($7.47) per share. HC Wainwright also issued estimates for Mural Oncology’s Q4 2024 earnings at ($2.09) EPS, FY2024 earnings at ($7.85) EPS, Q1 2025 earnings at ($2.12) EPS, Q2 2025 earnings at ($1.45) EPS, Q3 2025 earnings at ($1.47) EPS, Q4 2025 earnings at ($1.48) EPS, FY2025 earnings at ($6.52) EPS, FY2026 earnings at ($4.56) EPS, FY2027 earnings at ($3.09) EPS and FY2028 earnings at ($2.41) EPS.

A number of other equities research analysts have also recently weighed in on the company. Rodman & Renshaw assumed coverage on Mural Oncology in a report on Friday, June 28th. They issued a “buy” rating and a $15.00 price target on the stock. Raymond James assumed coverage on Mural Oncology in a report on Friday, October 4th. They issued a “strong-buy” rating and a $18.00 price target on the stock.

Mural Oncology Trading Down 1.1 %

Shares of MURA stock opened at $3.65 on Monday. The company has a market cap of $61.77 million and a price-to-earnings ratio of -0.35. The stock has a 50 day simple moving average of $3.28 and a 200-day simple moving average of $3.43. Mural Oncology has a 12-month low of $2.88 and a 12-month high of $17.00.

Mural Oncology (NASDAQ:MURA) last issued its earnings results on Tuesday, August 13th. The company reported ($1.86) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.90) by $0.04.

Institutional Investors Weigh In On Mural Oncology

A number of institutional investors and hedge funds have recently modified their holdings of the company. Acadian Asset Management LLC acquired a new stake in Mural Oncology during the 2nd quarter valued at $998,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Mural Oncology during the 2nd quarter valued at $84,000. Armistice Capital LLC acquired a new stake in shares of Mural Oncology during the second quarter worth $5,300,000. Primecap Management Co. CA acquired a new stake in shares of Mural Oncology during the second quarter worth $740,000. Finally, Canada Pension Plan Investment Board acquired a new stake in shares of Mural Oncology during the second quarter worth $70,000. Institutional investors and hedge funds own 80.21% of the company’s stock.

Mural Oncology Company Profile

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.